Here are five takeaways:
1. The company adjourned the meeting to provide for the “solicitation of additional votes in favor of the proposal contained in the definitive proxy statement” it filed July 28 with the Securities and Exchange Commission.
2. The statement regarded a reverse split of Amedica’s common stock, and requires approval of a majority of outstanding shares.
3. As of today, more than 13 million shares remained unvoted.
4. The stockholder meeting will commence Sept. 21. In the meantime, Amedica will solicit proxies from its stockholders.
5. Two leading independent proxy advisory firms suggest stockholder vote in favor of the reverse split.
More articles on devices:
Medtronic receives recognition for social responsibility: 5 takeaways
Medacta hosts 250th MORE AMIS Learning Center: 7 things to know
NuVasive receives FDA clearance for redesigned Magec system: 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
